Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 122

1.

Molecular dynamics simulation-guided drug sensitivity prediction for lung cancer with rare EGFR mutations.

Ikemura S, Yasuda H, Matsumoto S, Kamada M, Hamamoto J, Masuzawa K, Kobayashi K, Manabe T, Arai D, Nakachi I, Kawada I, Ishioka K, Nakamura M, Namkoong H, Naoki K, Ono F, Araki M, Kanada R, Ma B, Hayashi Y, Mimaki S, Yoh K, Kobayashi SS, Kohno T, Okuno Y, Goto K, Tsuchihara K, Soejima K.

Proc Natl Acad Sci U S A. 2019 May 14;116(20):10025-10030. doi: 10.1073/pnas.1819430116. Epub 2019 May 1.

2.

Prognostic differences between oligometastatic and polymetastatic extensive disease-small cell lung cancer.

Shirasawa M, Fukui T, Kusuhara S, Harada S, Nishinarita N, Hiyoshi Y, Ishihara M, Kasajima M, Igawa S, Yokoba M, Mitsufuji H, Kubota M, Katagiri M, Sasaki J, Naoki K.

PLoS One. 2019 Apr 19;14(4):e0214599. doi: 10.1371/journal.pone.0214599. eCollection 2019.

3.

Evaluation of osimertinib efficacy according to body surface area and body mass index in patients with non-small cell lung cancer harboring an EGFR mutation: A prospective observational study.

Ono T, Igawa S, Ozawa T, Kasajima M, Ishihara M, Hiyoshi Y, Kusuhara S, Nishinarita N, Fukui T, Kubota M, Sasaki J, Hisashi M, Katagiri M, Naoki K.

Thorac Cancer. 2019 Apr;10(4):880-889. doi: 10.1111/1759-7714.13018. Epub 2019 Feb 28.

PMID:
30821083
4.

Efficacy and risk of cytotoxic chemotherapy in extensive disease-small cell lung cancer patients with interstitial pneumonia.

Shirasawa M, Fukui T, Kusuhara S, Hiyoshi Y, Nakahara Y, Nishinarita N, Igawa S, Naoki K.

BMC Cancer. 2019 Feb 20;19(1):163. doi: 10.1186/s12885-019-5367-0.

5.

Clinicopathological and prognostic significance of nuclear UGDH localization in lung adenocarcinoma.

Hagiuda D, Nagashio R, Ichinoe M, Tsuchiya B, Igawa S, Naoki K, Satoh Y, Murakumo Y, Saegusa M, Sato Y.

Biomed Res. 2019;40(1):17-27. doi: 10.2220/biomedres.40.17.

6.

Phylogeographic variation within the Buff-browed Foliage-gleaner (Aves: Furnariidae: Syndactyla rufosuperciliata) supports an Andean-Atlantic forests connection via the Cerrado.

Cabanne GS, Campagna L, Trujillo-Arias N, Naoki K, Gómez I, Miyaki CY, Santos FR, Dantas GPM, Aleixo A, Claramunt S, Rocha A, Caparroz R, Lovette IJ, Tubaro PL.

Mol Phylogenet Evol. 2019 Apr;133:198-213. doi: 10.1016/j.ympev.2019.01.011. Epub 2019 Jan 17.

PMID:
30660755
7.

Prospective evaluation of the G8 screening tool for prognostication of survival in elderly patients with lung cancer: A single-institution study.

Agemi Y, Shimokawa T, Sasaki J, Miyazaki K, Misumi Y, Sato A, Aida S, Ishii M, Nakamura Y, Naoki K, Okamoto H.

PLoS One. 2019 Jan 17;14(1):e0210499. doi: 10.1371/journal.pone.0210499. eCollection 2019.

8.

Questionnaire survey on patient awareness of invasive rebiopsy in advanced non-small cell lung cancer.

Fukui T, Ishihara M, Kasajima M, Hiyoshi Y, Nakahara Y, Otani S, Igawa S, Yokoba M, Mitsufuji H, Kubota M, Katagiri M, Sasaki J, Naoki K.

Thorac Cancer. 2019 Mar;10(3):501-507. doi: 10.1111/1759-7714.12964. Epub 2019 Jan 16.

9.

Efficacy of afatinib or osimertinib plus cetuximab combination therapy for non-small-cell lung cancer with EGFR exon 20 insertion mutations.

Hasegawa H, Yasuda H, Hamamoto J, Masuzawa K, Tani T, Nukaga S, Hirano T, Kobayashi K, Manabe T, Terai H, Ikemura S, Kawada I, Naoki K, Soejima K.

Lung Cancer. 2019 Jan;127:146-152. doi: 10.1016/j.lungcan.2018.11.039. Epub 2018 Nov 29.

PMID:
30642543
10.

Real-world evaluation of carboplatin plus a weekly dose of nab-paclitaxel for patients with advanced non-small-cell lung cancer with interstitial lung disease.

Igawa S, Nishinarita N, Takakura A, Ozawa T, Harada S, Kusuhara S, Niwa H, Hosotani S, Sone H, Nakahara Y, Fukui T, Mitsufuji H, Yokoba M, Kubota M, Katagiri M, Sasaki J, Naoki K.

Cancer Manag Res. 2018 Dec 14;10:7013-7019. doi: 10.2147/CMAR.S189556. eCollection 2018.

11.

Prognostic significance of the 8th edition of the TNM classification for patients with extensive disease small cell lung cancer.

Shirasawa M, Fukui T, Kusuhara S, Hiyoshi Y, Ishihara M, Kasajima M, Nakahara Y, Otani S, Igawa S, Yokoba M, Mitsufuji H, Kubota M, Katagiri M, Sasaki J, Naoki K.

Cancer Manag Res. 2018 Nov 21;10:6039-6047. doi: 10.2147/CMAR.S181789. eCollection 2018.

12.

Amrubicin monotherapy for elderly patients with relapsed extensive-disease small-cell lung cancer: A retrospective study.

Sone H, Igawa S, Kasajima M, Ishihara M, Hiyoshi Y, Hosotani S, Ohe S, Ito H, Kaizuka N, Manaka H, Fukui T, Mitsufuji H, Kubota M, Katagiri M, Sasaki J, Naoki K.

Thorac Cancer. 2018 Oct;9(10):1279-1284. doi: 10.1111/1759-7714.12833. Epub 2018 Aug 20.

13.

Prognostic Understanding at Diagnosis and Associated Factors in Patients with Advanced Lung Cancer and Their Caregivers.

Sato T, Soejima K, Fujisawa D, Takeuchi M, Arai D, Nakachi I, Naoki K, Kawada I, Yasuda H, Ishioka K, Nukaga S, Kobayashi K, Masaki K, Inoue T, Hikima K, Nakamura M, Ohgino K, Oyamada Y, Funatsu Y, Terashima T, Miyao N, Sayama K, Saito F, Sakamaki F, Betsuyaku T.

Oncologist. 2018 Oct;23(10):1218-1229. doi: 10.1634/theoncologist.2017-0329. Epub 2018 Aug 17.

PMID:
30120158
14.

Comparison of detection methods of EGFR T790M mutations using plasma, serum, and tumor tissue in EGFR-TKI-resistant non-small cell lung cancer.

Kobayashi K, Naoki K, Manabe T, Masuzawa K, Hasegawa H, Yasuda H, Kawada I, Soejima K, Betsuyaku T.

Onco Targets Ther. 2018 Jun 6;11:3335-3343. doi: 10.2147/OTT.S161745. eCollection 2018.

15.

Intracranial Response to Nivolumab in a Patient with PD-L1-negative Lung Adenocarcinoma.

Nakahara Y, Fukui T, Shirasawa M, Harada S, Kusuhara S, Takakura A, Yokoba M, Mitsufuji H, Kubota M, Katagiri M, Sasaki J, Masuda N, Inukai M, Sekiguchi T, Naoki K.

Intern Med. 2018 Nov 1;57(21):3149-3152. doi: 10.2169/internalmedicine.9884-17. Epub 2018 Jun 6.

16.

Comparison of carboplatin plus etoposide with amrubicin monotherapy for extensive-disease small cell lung cancer in the elderly and patients with poor performance status.

Igawa S, Shirasawa M, Ozawa T, Nishinarita N, Okuma Y, Ono T, Sugimoto A, Kurahayashi S, Sugita K, Sone H, Fukui T, Mitsufuji H, Kubota M, Katagiri M, Sasaki J, Naoki K.

Thorac Cancer. 2018 Aug;9(8):967-973. doi: 10.1111/1759-7714.12772. Epub 2018 Jun 5.

17.

Activity of Nivolumab and Utility of Neutrophil-to-Lymphocyte Ratio as a Predictive Biomarker for Advanced Non-Small-Cell Lung Cancer: A Prospective Observational Study.

Fukui T, Okuma Y, Nakahara Y, Otani S, Igawa S, Katagiri M, Mitsufuji H, Kubota M, Hiyoshi Y, Ishihara M, Kasajima M, Sasaki J, Naoki K.

Clin Lung Cancer. 2019 May;20(3):208-214.e2. doi: 10.1016/j.cllc.2018.04.021. Epub 2018 May 5.

PMID:
29803573
18.

Prognostic significance of G6PD expression and localization in lung adenocarcinoma.

Nagashio R, Oikawa S, Yanagita K, Hagiuda D, Kuchitsu Y, Igawa S, Naoki K, Satoh Y, Ichinoe M, Murakumo Y, Saegusa M, Sato Y.

Biochim Biophys Acta Proteins Proteom. 2019 Jan;1867(1):38-46. doi: 10.1016/j.bbapap.2018.05.005. Epub 2018 May 9.

PMID:
29753088
19.

Smoking History as a Predictor of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Non-Small Cell Lung Cancer Harboring EGFR Mutations.

Nishinarita N, Igawa S, Kasajima M, Kusuhara S, Harada S, Okuma Y, Sugita K, Ozawa T, Fukui T, Mitsufuji H, Yokoba M, Katagiri M, Kubota M, Sasaki J, Naoki K.

Oncology. 2018;95(2):109-115. doi: 10.1159/000488594. Epub 2018 Apr 26.

PMID:
29698957
20.

Tumor associated macrophages support the growth of FGF9-induced lung adenocarcinoma by multiple mechanisms.

Hegab AE, Ozaki M, Kagawa S, Hamamoto J, Yasuda H, Naoki K, Soejima K, Yin Y, Kinoshita T, Yaguchi T, Kawakami Y, Ornitz DM, Betsuyaku T.

Lung Cancer. 2018 May;119:25-35. doi: 10.1016/j.lungcan.2018.02.015. Epub 2018 Mar 2.

PMID:
29656749
21.

Targeted Therapy-induced Facial Skin Toxicities: Impact on Quality of Life in Cancer Patients.

Yagasaki K, Komatsu H, Soejima K, Naoki K, Kawada I, Yasuda H, Hamamoto Y.

Asia Pac J Oncol Nurs. 2018 Apr-Jun;5(2):172-177. doi: 10.4103/apjon.apjon_74_17.

22.

Secondary Brain Neoplasm after Stereotactic Radiosurgery in Patients with Metastatic Non-small Cell Lung Cancer.

Nukaga S, Naoki K, Yasuda H, Kawada I, Ohara K, Soejima K, Betsuyaku T.

Intern Med. 2018 Aug 15;57(16):2383-2387. doi: 10.2169/internalmedicine.0184-17. Epub 2018 Mar 9.

23.

Development of Necrotizing Myopathy Following Interstitial Lung Disease with Anti-signal Recognition Particle Antibody.

Kusumoto T, Okamori S, Masuzawa K, Asakura T, Nishina N, Chubachi S, Naoki K, Fukunaga K, Betsuyaku T.

Intern Med. 2018 Jul 15;57(14):2045-2049. doi: 10.2169/internalmedicine.0303-17. Epub 2018 Feb 28.

24.

Pharmacological and Structural Characterizations of Naquotinib, a Novel Third-Generation EGFR Tyrosine Kinase Inhibitor, in EGFR-Mutated Non-Small Cell Lung Cancer.

Hirano T, Yasuda H, Hamamoto J, Nukaga S, Masuzawa K, Kawada I, Naoki K, Niimi T, Mimasu S, Sakagami H, Soejima K, Betsuyaku T.

Mol Cancer Ther. 2018 Apr;17(4):740-750. doi: 10.1158/1535-7163.MCT-17-1033. Epub 2018 Feb 21.

25.

Real-world Efficacy and Safety of Nivolumab for Advanced Non-Small-cell Lung Cancer: A Retrospective Multicenter Analysis.

Kobayashi K, Nakachi I, Naoki K, Satomi R, Nakamura M, Inoue T, Tateno H, Sakamaki F, Sayama K, Terashima T, Koh H, Abe T, Nishino M, Arai D, Yasuda H, Kawada I, Soejima K, Betsuyaku T; Keio Lung Oncology Group (KLOG).

Clin Lung Cancer. 2018 May;19(3):e349-e358. doi: 10.1016/j.cllc.2018.01.001. Epub 2018 Jan 5.

PMID:
29398578
26.

Efficacy of Platinum-Based Chemotherapy for Relapsed Small-Cell Lung Cancer after Amrubicin Monotherapy in Elderly Patients and Patients with Poor Performance Status.

Igawa S, Shirasawa M, Fukui T, Nishinarita N, Sone H, Ozawa T, Sugita K, Okuma Y, Kurahayashi S, Ono T, Sugimoto A, Mitsufuji H, Kubota M, Katagiri M, Sasaki J, Naoki K.

Oncology. 2018;94(4):207-214. doi: 10.1159/000486038. Epub 2018 Jan 31.

PMID:
29393275
27.

Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutations.

Masuzawa K, Yasuda H, Hamamoto J, Nukaga S, Hirano T, Kawada I, Naoki K, Soejima K, Betsuyaku T.

Oncotarget. 2017 Nov 6;8(62):105479-105491. doi: 10.18632/oncotarget.22297. eCollection 2017 Dec 1.

28.

EGFR-mutant Non-small Cell Lung Cancer Accompanied by Transient Asymptomatic Pulmonary Opacities Successfully Treated with "Stop-And-Go" Osimertinib.

Kobayashi K, Naoki K, Kuroda A, Yasuda H, Kawada I, Soejima K, Betsuyaku T.

Intern Med. 2018 Apr 1;57(7):1007-1010. doi: 10.2169/internalmedicine.9609-17. Epub 2017 Dec 21.

29.

Non-small cell lung cancer PC-9 cells exhibit increased sensitivity to gemcitabine and vinorelbine upon acquiring resistance to EGFR-tyrosine kinase inhibitors.

Hamamoto J, Yasuda H, Aizawa K, Nishino M, Nukaga S, Hirano T, Kawada I, Naoki K, Betsuyaku T, Soejima K.

Oncol Lett. 2017 Sep;14(3):3559-3565. doi: 10.3892/ol.2017.6591. Epub 2017 Jul 18.

30.

Variant CD44 expression is enriching for a cell population with cancer stem cell-like characteristics in human lung adenocarcinoma.

Nishino M, Ozaki M, Hegab AE, Hamamoto J, Kagawa S, Arai D, Yasuda H, Naoki K, Soejima K, Saya H, Betsuyaku T.

J Cancer. 2017 Jul 1;8(10):1774-1785. doi: 10.7150/jca.19732. eCollection 2017.

31.

Radiologic features of precancerous areas of the lungs in chronic obstructive pulmonary disease.

Chubachi S, Takahashi S, Tsutsumi A, Kameyama N, Sasaki M, Naoki K, Soejima K, Nakamura H, Asano K, Betsuyaku T.

Int J Chron Obstruct Pulmon Dis. 2017 May 30;12:1613-1624. doi: 10.2147/COPD.S132709. eCollection 2017.

32.

Clinical and pathological characteristics of EGFR mutation in operable early-stage lung adenocarcinoma.

Yotsukura M, Yasuda H, Shigenobu T, Kaseda K, Masai K, Hayashi Y, Hishida T, Ohtsuka T, Naoki K, Soejima K, Betsuyaku T, Asamura H.

Lung Cancer. 2017 Jul;109:45-51. doi: 10.1016/j.lungcan.2017.04.014. Epub 2017 Apr 23.

PMID:
28577949
33.

Phase I/II study of induction chemotherapy using carboplatin plus irinotecan and sequential thoracic radiotherapy (TRT) for elderly patients with limited-disease small-cell lung cancer (LD-SCLC): TORG 0604.

Misumi Y, Okamoto H, Sasaki J, Masuda N, Ishii M, Shimokawa T, Hosomi Y, Okuma Y, Nagamata M, Ogura T, Kato T, Sata M, Otani S, Takakura A, Minato K, Miura Y, Yokoyama T, Takata S, Naoki K, Watanabe K.

BMC Cancer. 2017 May 26;17(1):377. doi: 10.1186/s12885-017-3353-y.

34.

A prospective cohort study of patients with non-squamous non-small cell lung cancer treated with bevacizumab.

Naoki K, Takeda Y, Soejima K, Arai D, Naka G, Nagase S, Arimura K, Kanemura T, Ohhira T, Ikeda N.

Oncol Lett. 2017 May;13(5):3285-3290. doi: 10.3892/ol.2017.5796. Epub 2017 Mar 2.

35.

Erlotinib as second- or third-line treatment in elderly patients with advanced non-small cell lung cancer: Keio Lung Oncology Group Study 001 (KLOG001).

Miyawaki M, Naoki K, Yoda S, Nakayama S, Satomi R, Sato T, Ikemura S, Ohgino K, Ishioka K, Arai D, Namkoong H, Otsuka K, Miyazaki M, Tani T, Kuroda A, Nishino M, Yasuda H, Kawada I, Koh H, Nakamura M, Terashima T, Sakamaki F, Sayama K, Betsuyaku T, Soejima K.

Mol Clin Oncol. 2017 Mar;6(3):409-414. doi: 10.3892/mco.2017.1154. Epub 2017 Feb 6.

36.

The niche and phylogeography of a passerine reveal the history of biological diversification between the Andean and the Atlantic forests.

Trujillo-Arias N, Dantas GPM, Arbeláez-Cortés E, Naoki K, Gómez MI, Santos FR, Miyaki CY, Aleixo A, Tubaro PL, Cabanne GS.

Mol Phylogenet Evol. 2017 Jul;112:107-121. doi: 10.1016/j.ympev.2017.03.025. Epub 2017 Apr 3.

37.

Amplification of EGFR Wild-Type Alleles in Non-Small Cell Lung Cancer Cells Confers Acquired Resistance to Mutation-Selective EGFR Tyrosine Kinase Inhibitors.

Nukaga S, Yasuda H, Tsuchihara K, Hamamoto J, Masuzawa K, Kawada I, Naoki K, Matsumoto S, Mimaki S, Ikemura S, Goto K, Betsuyaku T, Soejima K.

Cancer Res. 2017 Apr 15;77(8):2078-2089. doi: 10.1158/0008-5472.CAN-16-2359. Epub 2017 Feb 15.

38.

A Case of Non-Small Cell Lung Cancer with Possible "Disease Flare" on Nivolumab Treatment.

Chubachi S, Yasuda H, Irie H, Fukunaga K, Naoki K, Soejima K, Betsuyaku T.

Case Rep Oncol Med. 2016;2016:1075641. doi: 10.1155/2016/1075641. Epub 2016 Dec 27.

39.

Overcoming EGFR Bypass Signal-Induced Acquired Resistance to ALK Tyrosine Kinase Inhibitors in ALK-Translocated Lung Cancer.

Miyawaki M, Yasuda H, Tani T, Hamamoto J, Arai D, Ishioka K, Ohgino K, Nukaga S, Hirano T, Kawada I, Naoki K, Hayashi Y, Betsuyaku T, Soejima K.

Mol Cancer Res. 2017 Jan;15(1):106-114. doi: 10.1158/1541-7786.MCR-16-0211. Epub 2016 Oct 5.

40.

Successful treatment of non-small-cell lung cancer with afatinib and a glucocorticoid following gefitinib- and erlotinib-induced interstitial lung disease: A case report.

Tani T, Naoki K, Asakura T, Hirano T, Suzuki S, Masuzawa K, Hasegawa H, Kuroda A, Yasuda H, Ishii M, Soejima K, Betsuyaku T.

Mol Clin Oncol. 2016 Oct;5(4):488-490. Epub 2016 Aug 4.

41.

Positive feedback promotes mitotic exit via the APC/C-Cdh1-separase-Cdc14 axis in budding yeast.

Hatano Y, Naoki K, Suzuki A, Ushimaru T.

Cell Signal. 2016 Oct;28(10):1545-54. doi: 10.1016/j.cellsig.2016.07.005. Epub 2016 Jul 11.

PMID:
27418100
42.
43.

Activation of EGFR Bypass Signaling by TGFα Overexpression Induces Acquired Resistance to Alectinib in ALK-Translocated Lung Cancer Cells.

Tani T, Yasuda H, Hamamoto J, Kuroda A, Arai D, Ishioka K, Ohgino K, Miyawaki M, Kawada I, Naoki K, Hayashi Y, Betsuyaku T, Soejima K.

Mol Cancer Ther. 2016 Jan;15(1):162-71. doi: 10.1158/1535-7163.MCT-15-0084. Epub 2015 Dec 18.

44.

In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer.

Hirano T, Yasuda H, Tani T, Hamamoto J, Oashi A, Ishioka K, Arai D, Nukaga S, Miyawaki M, Kawada I, Naoki K, Costa DB, Kobayashi SS, Betsuyaku T, Soejima K.

Oncotarget. 2015 Nov 17;6(36):38789-803. doi: 10.18632/oncotarget.5887.

45.

Fatal Fulminant Pneumonia Caused by Methicillin-Sensitive Staphylococcus aureus Negative for Major High-Virulence Factors Following Influenza B Virus Infection.

Masaki K, Ishii M, Anraku M, Namkoong H, Miyakawa R, Nakajima T, Fukunaga K, Naoki K, Tasaka S, Soejima K, Sayama K, Sugita K, Iwata S, Cui L, Hanaki H, Hasegawa N, Betsuyaku T.

Am J Case Rep. 2015 Jul 14;16:454-8. doi: 10.12659/AJCR.894022.

46.

Prognostic implication of PTPRH hypomethylation in non-small cell lung cancer.

Sato T, Soejima K, Arai E, Hamamoto J, Yasuda H, Arai D, Ishioka K, Ohgino K, Naoki K, Kohno T, Tsuta K, Watanabe S, Kanai Y, Betsuyaku T.

Oncol Rep. 2015 Sep;34(3):1137-45. doi: 10.3892/or.2015.4082. Epub 2015 Jun 25.

47.

Mimicking the niche of lung epithelial stem cells and characterization of several effectors of their in vitro behavior.

Hegab AE, Arai D, Gao J, Kuroda A, Yasuda H, Ishii M, Naoki K, Soejima K, Betsuyaku T.

Stem Cell Res. 2015 Jul;15(1):109-21. doi: 10.1016/j.scr.2015.05.005. Epub 2015 May 20.

48.

Continental-scale analysis reveals deep diversification within the polytypic Red-crowned Ant Tanager (Habia rubica, Cardinalidae).

Lavinia PD, Escalante P, García NC, Barreira AS, Trujillo-Arias N, Tubaro PL, Naoki K, Miyaki CY, Santos FR, Lijtmaer DA.

Mol Phylogenet Evol. 2015 Aug;89:182-93. doi: 10.1016/j.ympev.2015.04.018. Epub 2015 Apr 27.

PMID:
25929787
49.

A Phase II study of S-1 and irinotecan combination therapy in previously treated patients with advanced non-small cell lung cancer.

Ikemura S, Naoki K, Yasuda H, Kawada I, Yoda S, Terai H, Sato T, Ishioka K, Arai D, Ohgino K, Kamata H, Miyata J, Kabata H, Betsuyaku T, Soejima K.

Jpn J Clin Oncol. 2015 Apr;45(4):356-61. doi: 10.1093/jjco/hyu226. Epub 2015 Jan 22.

PMID:
25612761
50.

A phase II study of biweekly paclitaxel and carboplatin in elderly patients with advanced non-small cell lung cancer.

Soejima K, Naoki K, Ishioka K, Nakamura M, Nakatani M, Kawada I, Watanabe H, Nakachi I, Yasuda H, Satomi R, Nakayama S, Yoda S, Ikemura S, Terai H, Sato T, Ohgino K, Arai D, Tani T, Kuroda A, Nishino M, Betsuyaku T.

Cancer Chemother Pharmacol. 2015 Mar;75(3):513-9. doi: 10.1007/s00280-014-2673-8. Epub 2015 Jan 7.

PMID:
25563719

Supplemental Content

Support Center